Ann: Appendix 4C - March 2019 Quarterly Report, page-52

Hi Jason & Welcome

Some other things in PIQ IP to consider, and there are more, but some that really have piqued my interest:

New patent for biomarker in abnormal kidney function & drug development granted in USA
https://www.asx.com.au/asxpdf/20190221/pdf/442tgnzpnfvks0.pdf

Also looking forward to news on Giardiasis test & something I think that will be really big, a test for endometriosis. 1 in 10 women suffer from this, which can be very debilitating & affect fertility & QOL. Exploratory surgery to confirm diagnosis is not always ideal. PIQ have stated in a recent announcement work on biomarkers are almost completed.

There is increased interest & awareness of Endometriosis, including a working party instigated by the Australian Govt to increase awareness for GPs & Healthcare providers & develop an Action Plan:

https://www.health.gov.au/internet/main/publishing.nsf/Content/58AD1EF08402AC9FCA2582D5001A271E/$File/National%20Action%20Plan%20for%20Endometriosis.pdf

Multiple Big Pharma are developing non-opioid drugs to treat associated pain. Just one example:

https://www.orilissa.com

We haven’t heard anything about the collaboration with Atturos & Prostate Insitu test & mass spectrometry recently, but looking like this Irish company out of Dublin University are on track for their test to be available on market for mid 2020.

https://www.asx.com.au/asxpdf/20181030/pdf/43zs145sx2344d.pdf

https://www.asx.com.au/asxpdf/20180919/pdf/43yg1jykmk8grs.pdf

Atturos website, looking good!:

http://atturos.com/ocprodx/prostate-cancer/

While PromarkerD may be the perceived jewel in the crown for PIQ, there is a lot more in the pipeline that we should probably be keeping our eye on as Investors too.

Best Wishes All